

BelÃ©n BeltrÃ¡n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5776216/publications.pdf>

Version: 2024-02-01

53
papers

1,996
citations

279701

23
h-index

243529

44
g-index

56
all docs

56
docs citations

56
times ranked

3091
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxidative stress and S-nitrosylation of proteins in cells. <i>British Journal of Pharmacology</i> , 2000, 129, 953-960.	2.7	186
2	Evaluation of postsurgical recurrence in Crohn's disease: a new indication for capsule endoscopy?. <i>Gastrointestinal Endoscopy</i> , 2007, 66, 533-540.	0.5	156
3	Inhibition of mitochondrial respiration by endogenous nitric oxide: A critical step in Fas signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 8892-8897.	3.3	122
4	Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naïve and treated Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 76-86.	0.9	110
5	Study of the Viral and Microbial Communities Associated With Crohn's Disease: A Metagenomic Approach. <i>Clinical and Translational Gastroenterology</i> , 2013, 4, e36.	1.3	108
6	Ulcerative colitis in smokers, non-smokers and ex-smokers. <i>World Journal of Gastroenterology</i> , 2011, 17, 2740.	1.4	102
7	Role of oxidative stress and antioxidant enzymes in Crohn's disease. <i>Biochemical Society Transactions</i> , 2011, 39, 1102-1106.	1.6	90
8	Assessing an Improved Protocol for Plasma microRNA Extraction. <i>PLoS ONE</i> , 2013, 8, e82753.	1.1	81
9	Epidemiological risk factors in microscopic colitis: a prospective case-control study. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 411-7.	0.9	80
10	Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2515-2532.	0.9	79
11	Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. <i>World Journal of Gastroenterology</i> , 2012, 18, 4391.	1.4	78
12	Infliximab and adalimumab-induced psoriasis in Crohn's disease: A paradoxical side effect. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 157-161.	0.6	72
13	Fecal Calprotectin in Ileal Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1572-1579.	0.9	55
14	Impact of Current Smoking on the Clinical Course of Microscopic Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1470-1476.	0.9	54
15	Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. <i>Journal of Gastroenterology</i> , 2017, 52, 788-799.	2.3	50
16	Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1387-1391.	0.9	43
17	Oxidative Stress in the Pathogenesis of Crohn's Disease and the Interconnection with Immunological Response, Microbiota, External Environmental Factors, and Epigenetics. <i>Antioxidants</i> , 2021, 10, 64.	2.2	41
18	Possible Biomarkers in Blood for Crohn's Disease: Oxidative Stress and MicroRNAs—Current Evidences and Further Aspects to Unravel. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-9.	1.9	39

#	ARTICLE	IF	CITATIONS
19	Continuous exposure to high concentrations of nitric oxide leads to persistent inhibition of oxygen consumption by J774 cells as well as extraction of oxygen by the extracellular medium. <i>Biochemical Journal</i> , 2000, 346, 407-412.	1.7	35
20	Small intestinal bacterial overgrowth in inactive Crohn's disease: Influence of thiopurine and biological treatment. <i>World Journal of Gastroenterology</i> , 2014, 20, 13999.	1.4	34
21	Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease. <i>Digestive Diseases</i> , 2019, 37, 108-115.	0.8	32
22	Influence of Vitamin D Deficiency on Inflammatory Markers and Clinical Disease Activity in IBD Patients. <i>Nutrients</i> , 2019, 11, 1059.	1.7	30
23	A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1681-1691.	0.9	28
24	Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1454-1460.	0.9	25
25	Identification of Epigenetic Methylation Signatures With Clinical Value in Crohn's Disease. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00083.	1.3	22
26	Synthesis of nitric oxide in the dorsal motor nucleus of the vagus mediates the inhibition of gastric acid secretion by central bombesin. <i>British Journal of Pharmacology</i> , 1999, 127, 1603-1610.	2.7	21
27	Role of the Endothelium in the Relaxation Induced by Propofol and Thiopental in Isolated Arteries from Man. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 49, 430-432.	1.2	19
28	Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 459-464.	0.6	17
29	Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 152-157.	0.6	16
30	Continuous exposure to high concentrations of nitric oxide leads to persistent inhibition of oxygen consumption by J774 cells as well as extraction of oxygen by the extracellular medium. <i>Biochemical Journal</i> , 2000, 346, 407.	1.7	15
31	Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2016, 26, 641-656.	0.6	14
32	Superoxide dismutase and catalase anti-oxidant activity in leucocyte lysates from hypertensive patients: effects of eprosartan treatment. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2009, 10, 24-30.	1.0	13
33	Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1417-1425.	1.1	12
34	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 1: epidemiología, diagnóstico y pronóstico. <i>Gastroenterología y Hepatología</i> , 2019, 42, 568-578.	0.2	11
35	Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease. <i>Journal of Surgical Research</i> , 2017, 213, 290-297.	0.8	10
36	Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , 2019, 11, 1062.	1.7	8

#	ARTICLE	IF	CITATIONS
37	Plasma Oncostatin M, TNF- α , IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop. <i>Digestive Diseases</i> , 2021, 39, 1-9.	0.8	8
38	Recomendaciones del Grupo Espaol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento. <i>GastroenterologA Y HepatologA</i> , 2020, 43, 649-658.	0.2	7
39	Specific Plasma MicroRNA Signatures in Predicting and Confirming Crohn's Disease Recurrence: Role and Pathogenic Implications. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00416.	1.3	7
40	Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF- α drug failure. <i>Digestive and Liver Disease</i> , 2018, 50, 415-417.	0.4	6
41	Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1612-1621.	1.1	6
42	Recomendaciones del Grupo Espaol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la infecci3n tuberculosa en pacientes con enfermedad inflamatoria intestinal. <i>GastroenterologA Y HepatologA</i> , 2021, 44, 51-66.	0.2	5
43	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease. <i>GastroenterologA Y HepatologA (English Edition)</i> , 2021, 44, 51-66.	0.0	4
44	Effects of Endotoxin on Neurally-mediated Gastric Acid Secretion in the Rat. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 49, 1239-1241.	1.2	3
45	Mo1685 Fecal Calprotectin (FC) is a Useful Early Predictive Marker for Postoperative Recurrence in Crohn's Disease (CD). <i>Gastroenterology</i> , 2012, 142, S-659.	0.6	3
46	Vedolizumab, una opci3n en pacientes con enfermedad inflamatoria intestinal intolerantes a tiopurinas y refractarios a biol3gicos. <i>GastroenterologA Y HepatologA</i> , 2018, 41, 535-543.	0.2	3
47	Different Genetic Expression Profiles of Oxidative Stress and Apoptosis-Related Genes in Crohn's Disease. <i>Digestion</i> , 2019, 100, 27-36.	1.2	3
48	La resonancia magn3tica y el ndice MaRIA en la valoraci3n preoperatoria de la enfermedad de Crohn ileal. <i>CirugA Espaola</i> , 2019, 97, 582-589.	0.1	3
49	Tu1951 Apoptosis Resistance of Crohn's Disease Blood T-Cells Depends on Catalase Activity Inhibition. <i>Gastroenterology</i> , 2012, 142, S-885.	0.6	2
50	Adsorptive granulocyte/monocyte apheresis use in severe ulcerative colitis and determination of changes in plasma cytokines. <i>Journal of Clinical Apheresis</i> , 2018, 33, 99-103.	0.7	2
51	Videocapsule Endoscopy Versus Colonoscopy for the Diagnosis of Postsurgical Recurrence in Crohn's Disease (CD): A Pilot Study. <i>Gastrointestinal Endoscopy</i> , 2005, 61, AB159.	0.5	1
52	Response:. <i>Gastrointestinal Endoscopy</i> , 2008, 68, 203-204.	0.5	0
53	Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease" results from the ENEIDA registry. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 600-601.	1.9	0